Clinical trials are no longer a distant hope for the SYNGAP1 community — they’re getting closer every day, and families will soon have the opportunity to consider whether participation is right for them. As new treatment strategies move from laboratory research to human testing, families will play a crucial role in shaping the future of SYNGAP1 care. This post is designed to help you understand what clinical trials are, the types of treatments that may be evaluated, and how to begin preparing — emotionally, logistically, and medically — for upcoming SYNGAP1 clinical trials.
Additional information can be found in this blog: Emerging Medicines to Treat SYNGAP1-Related Disorders: Primer, Comparison, Glossary. Also see CURE SYNGAP1 Episode 202 – It is time to get ready for clinical trials, this is how. #S10e202.
1. What Is a Clinical Trial?
A clinical trial is a structured research study designed to test how a potential new treatment or intervention works in people. For rare genetic conditions like SYNGAP1-Related Disorders (SRD), clinical trials are the bridge between laboratory discoveries and real changes in children’s lives.
Each trial is built to answer three essential questions:
- Is it safe? — Does the therapy cause side effects, and how are they monitored?
- Does it work? — Does it lead to meaningful improvements in symptoms, development, or quality of life?
- What’s the right dose, and who benefits most? — Trials help determine the safest and most effective way to deliver a therapy.
Because rare conditions involve small, widely distributed populations, every participant’s data plays a meaningful role in answering these questions. Even when a treatment doesn’t produce the hoped-for result, the information gathered helps refine future approaches and improve care for all.
1.1 Why Clinical Trials Matter for Rare Diseases
For rare disorders, clinical trials aren’t just a scientific requirement — they’re a community effort. Every family that participates helps researchers learn how to measure change, what matters most to caregivers, and how to design better studies in the future.
Unlike conditions that affect thousands or millions of people, rare disease trials often rely on just a few dozen participants worldwide. That makes each family’s contribution profoundly important. By participating, families help transform individual experiences into collective progress — the kind of progress that eventually leads to approved treatments.
1.2 How Clinical Trials Are Structured
Clinical trials progress through a series of phases, each with a different purpose. For rare conditions, these phases may be combined (for example, a “Phase 1/2 trial”) to move efficiently while maintaining high safety standards.
| Phase | Purpose | Typical Size | Focus for Families |
| Phase 1 | Establishes safety and understands how the therapy behaves in the body. | Usually fewer than 20 participants. | May include tight inclusion criteria to make sure a positive signal will be seen if it is present. Involves close monitoring and frequent visits. |
| Phase 2 | Explores early signs of benefit and refines dose or delivery method. | Dozens of participants. | May require longer participation and travel. When placebo involved, drug typically available to all participants in Open Label Extension of the trial. |
| Phase 3 | Confirms efficacy compared to current care or placebo. Results can lead to FDA review. | Larger, often multi-site studies. | May require longer participation and travel. When placebo involved, drug typically available to all participants in Open Label Extension of the trial. |
| Phase 4 | Tracks long-term safety and effectiveness after approval. | Hundreds or more. | Conducted once a therapy is available; monitors real-world outcomes. |
These steps ensure that each trial stage for each new therapy builds on what was learned before, balancing urgency with caution.
1.3 What Happens During a Trial
Every clinical trial follows a protocol — a detailed roadmap that outlines exactly how the study will be conducted. The protocol ensures that every participant is treated consistently and that results can be trusted by regulators, doctors, and the broader research community.
The study protocol defines:
- Who can join: The inclusion and exclusion criteria describe which participants qualify for the study. These might include factors such as age, confirmed genetic diagnosis, seizure frequency, or other medical conditions. These rules help keep participants safe and ensure that results are meaningful.
- What procedures are performed: The protocol lists all tests and assessments — such as EEGs, bloodwork, behavioral surveys, or imaging — and how often each one occurs. This makes sure that every family’s experience follows the same structure.
- Which data are collected: Researchers specify what information is most important for evaluating the treatment, from lab values to caregiver reports and videos.
- How results will be analyzed: The plan details how data from all sites will be compared to determine whether the therapy is working and how safe it is.
By following the same protocol at every research site, scientists can confidently compare data across participants and locations, reducing bias and increasing the reliability of the findings. This consistency helps ensure that any changes seen in a child’s symptoms are truly due to the therapy — not differences in how the study was run.
1.4 Types of Rare Disease–Specific Trial Designs
Because rare disease trials involve smaller patient populations, researchers often use innovative and flexible study designs to make the most of every participant’s data. These designs allow progress to move faster while still maintaining strict safety and scientific standards.
Adaptive trials are one example. In a traditional study, the plan stays fixed from start to finish. In an adaptive trial, researchers can make thoughtful adjustments as new information emerges — such as changing the dose, expanding the eligible age range, or modifying how outcomes are measured. These changes are guided by pre-approved rules in the study protocol and are only made when early data show that they can improve safety or efficiency. For families, this approach can mean that trials evolve more quickly and that promising treatments reach children sooner.
Open-label extensions often follow the main part of a clinical trial. Once the initial study (which may include a placebo group) is complete, all participants are offered access to the real therapy. This allows researchers to collect long-term safety and benefit data, while giving families continued access to the treatment they helped test. Open-label extensions are especially common in rare diseases, where maintaining engagement and learning about long-term effects are both essential.
Natural history studies are not clinical trials but they are another key part of rare disease research. These studies follow individuals with the same genetic condition over time, without introducing a new treatment. The goal is to understand how symptoms change naturally — for example, how seizures, sleep, or development evolve as a child grows. This information becomes the foundation for measuring progress in future treatment trials. If researchers know the “natural” pattern of the disorder, they can more confidently tell whether a therapy is truly making a difference.
Together, these designs help maximize learning from every family’s participation. In rare disease research, where every single data point counts, creative and thoughtful study structures make it possible to move forward faster, more efficiently, and more meaningfully for the children and communities involved.
1.5 Safeguards That Protect Families
Participating in a clinical trial means joining a carefully regulated process with multiple layers of safety oversight. Every clinical trial in the U.S. must be reviewed and approved by an Institutional Review Board (IRB) — an independent committee that includes doctors, scientists, and community members. The IRB’s job is to make sure the study is ethical, safe, and understandable for participants. Before a trial begins, the IRB reviews the study and communication plan to confirm that families receive clear, honest information about what participation involves. The IRB continues to monitor the study as it runs and can pause it at any time if safety concerns arise. This oversight ensures that protecting participants always comes before scientific progress.
Before joining a trial, families receive a detailed document called informed consent. It explains the study’s purpose, what participation will involve, possible risks and benefits, and how information will be used. The goal is to help families make a fully informed choice. Signing consent is never a commitment to complete the study — participation in a clinical trial is always voluntary, and families can withdraw at any time.
Additional protections include:
- Data Safety Monitoring Board (DSMB): A group of independent experts that will regularly review study results to make sure participants stay safe. If they see any unexpected problems, they can recommend changes or even pause the trial.
- Confidentiality: Your child’s personal information will be kept private. Each participant is assigned a code number, and all data are stored securely in line with federal privacy laws (such as HIPAA).
- Medical oversight: Throughout the trial, study doctors and coordinators will closely monitor each participant’s health and progress. If any concerns come up, the team can adjust care right away to keep your child safe.
2. Types of Emerging SYNGAP1 Treatments
Three main approaches are now driving treatment development for SYNGAP1 and other neurodevelopmental disorders. Understanding these can help families anticipate what future trials might look like.
| Therapy Type | How It Works | Delivery Method | Family Considerations |
| ASO (Antisense Oligonucleotide) | Short synthetic strands of DNA-like material that modify how RNA is read — turning genes “up” or “down.” | Delivered into spinal fluid through a lumbar puncture (intrathecal injection). | Requires repeat dosing every 1–3 months; usually sedation; early-phase trials focus on safety and dosing. |
| AAV Gene Therapy | Uses a harmless virus (AAV) to deliver a healthy copy of the SYNGAP1 gene directly to cells. | One-time intrathecal or IV infusion. | Involves immune monitoring, steroids, and long-term follow-up; potential for lasting benefit but lifelong tracking is needed. |
| Small Molecules | Oral or injectable drugs that adjust pathways affected by SYNGAP1. | Pills or liquids. | Easier to administer, lower risk, and may be among the earliest trials to open. |
While there is not yet an active human SYNGAP1 treatment trial, several studies in related neurodevelopmental disorders are already underway. These programs are paving the way — showing what participation looks like, how families are supported, and what questions to ask when SYNGAP1 trials open.
2.1 Current ASO (Antisense Oligonucleotide) Trials:
- Angelman Syndrome — GTX-102 (Ultragenyx): A global Phase 3 trial is now enrolling, with additional expansion studies. Participants receive spinal injections every few months. Early studies saw temporary leg weakness at higher doses, which resolved — helping refine safer dosing for later trials.
- Dravet Syndrome — STK-001 (Stoke Therapeutics): The EMPEROR trial is a large, international Phase 3 study evaluating whether the ASO can reduce seizures and improve cognitive and behavioral outcomes in children with SCN1A mutations. This trial model — which includes close neurological monitoring and multiple dosing visits — offers a good example of what SYNGAP1 ASO studies may look like.
- MECP2 Duplication Syndrome — ION440 (Ionis): The ATTUNE Phase 1/2 study is now recruiting participants. It uses a similar lumbar puncture dosing method and visit schedule that would likely be used in future SYNGAP1 ASO trials.
What We’re Learning from ASO Trials
Early results from ongoing ASO trials in Angelman, Dravet, and MECP2 duplication syndromes are offering real insight into how these therapies may work — and what they can safely achieve.
Across these studies, researchers have seen encouraging signs of improvement in some children, including better seizure control, more consistent sleep, stronger communication, and measurable gains in developmental and behavioral assessments. In Dravet syndrome, for example, participants receiving repeat doses of STK-001 showed meaningful reductions in convulsive seizures and, in some cases, improvements in cognition and daily functioning. In the Angelman GTX-102 program, clinicians observed broad improvements in communication, alertness, and motor abilities after several months of treatment.
Just as importantly, these studies have helped define safe and tolerable dosing ranges through an iterative process — learning and refining with each phase. Early Angelman trials that reported temporary leg weakness at higher doses were paused, evaluated, and redesigned with lower doses and slower titration. The result has been safer administration and continued positive outcomes in later stages. Similarly, the Dravet studies established clear dosing windows that balance safety and benefit, with most side effects related to the spinal procedure itself (such as temporary headaches or back pain) rather than the drug.
Overall, these findings show that ASO delivery to the brain can be done safely in children when managed by experienced teams using careful monitoring protocols. Each trial adds valuable information about dose limits, monitoring needs, and how often lumbar punctures can safely occur — all of which will inform the design of future SYNGAP1 studies.
While the progress is promising, it’s important to remember that these are still early steps. Long-term benefits have not yet been proven, and outcomes may differ across genetic conditions. What we can say confidently is that the research community is learning quickly, refining approaches, and building a strong safety foundation for the next generation of trials — including those for SYNGAP1.
2.2 Current AAV (Gene Therapy) Trials:
Rett Syndrome — TSHA-102 (Taysha Gene Therapies): TSHA-102 is one of the most advanced AAV gene therapy programs for neurodevelopmental disorders. It uses an AAV9 vector to deliver a functional copy of the MECP2 gene directly to cells in the central nervous system through a single intrathecal (spinal) injection. This program has progressed from early adult dosing into pediatric trials and is now advancing toward pivotal testing. So far, results have been encouraging — participants have shown signs of improved alertness, communication, and breathing stability, with no dose-limiting safety issues reported. Families are carefully monitored for immune responses, liver function, and neurological health, reflecting the level of care that will be standard for future gene therapy studies.
GBA1 Parkinson’s Disease — PR001 (Prevail Therapeutics/Eli Lilly): Although focused on an adult neurological condition, the PR001 program has been pivotal in establishing safe systemic AAV delivery to the brain. Participants received a one-time intravenous infusion of AAV9 carrying the GBA1 gene, and the study demonstrated that systemic dosing can achieve meaningful levels of gene expression in the central nervous system while maintaining manageable safety. These data continue to shape how gene therapy is approached across brain disorders, including rare pediatric conditions.
What We’re Learning from AAV Trials
The current generation of AAV gene therapy programs has provided important insight into what families can expect — and how these treatments can be given safely. In both Rett syndrome and other AAV studies, researchers have confirmed that a single spinal or intravenous infusion can deliver therapeutic genes safely to the brain, with early signs of meaningful clinical improvements. Participants have shown better alertness, mobility, and cognitive engagement in the months following treatment. Importantly, these gains have occurred without serious immune reactions or long-term safety issues at approved doses.
These trials have also helped define safe dose ranges and clear safety protocols for immune suppression. Most programs now include short-term steroid use to prevent immune responses against the AAV vector and close laboratory monitoring of liver and blood markers in the weeks following dosing. The safety lessons from these studies — including how to manage immune risk and track long-term outcomes — are directly shaping how upcoming SYNGAP1 programs are being designed.
Another key lesson is the importance of long-term follow-up. Because AAV therapies are intended as one-time treatments that may last for years, families typically participate in follow-up visits for up to 5–10 years after dosing. These check-ins allow researchers to monitor sustained safety and durability of benefit, as well as any changes in immune status or gene expression over time.
Overall, the early AAV experience in Rett and other neurological conditions shows that gene therapy can be delivered safely to the central nervous system and may provide lasting benefit with a single dose. For SYNGAP1 families, these findings mean that when AAV trials open, they will build upon a growing foundation of knowledge about dosing, monitoring, and family support — bringing us one step closer to durable, gene-level treatments.
2.3 Current SYNGAP1 Treatment Pipeline
Although there is no approved therapy yet that corrects the underlying protein deficiency in SYNGAP1-Related Disorders, the research pipeline is active and advancing. CURE SYNGAP1 has mapped a range of strategies — from near-term repurposed drugs to next-generation gene therapies — that together bring hope for meaningful progress.
3. Participating in a Clinical Trial
Joining a clinical trial is both a scientific contribution and a personal decision. For families affected by SYNGAP1-Related Disorders, participation offers the chance to help move research forward — sometimes with potential access to promising treatments — but it also involves time, travel, and a structured schedule. Understanding what to expect can make the experience more manageable and help families decide whether participation is right for them.
3.1 What to Expect When Joining a Trial
Clinical trials follow a detailed plan that ensures every participant is treated consistently and safely. While each study is unique, most follow a similar sequence of steps:
- Screening and eligibility: Before enrolling, your child will go through tests and evaluations to confirm eligibility. This may include reviewing genetic results, seizure history, medications, developmental assessments, and basic health checks. The goal is to make sure the study is both safe and appropriate for your child’s situation.
- Informed consent: Families receive a clear, written explanation of the study — its purpose, procedures, potential risks and benefits, and their right to withdraw at any time. This process ensures you have all the information needed to make an informed choice before signing.
- Baseline and dosing visits: If your child qualifies, initial “baseline” assessments are done before treatment begins. These may include EEGs, blood tests, behavioral questionnaires, and physical exams. For interventional trials, the first dose (for example, a spinal injection in ASO or AAV studies, or an oral medication for small molecules) usually takes place at a clinical site equipped for close monitoring.
- Ongoing assessments: Trials often involve multiple visits over months or years, with some assessments done in person and others at home. Families can expect follow-ups such as EEGs, lab tests, seizure logs, caregiver surveys, and developmental evaluations. Most studies cover travel, lodging, and meal costs, and some provide home-visit options for certain procedures.
- Monitoring and follow-up: Safety is the top priority. Study coordinators, nurses, and physicians will check in frequently to monitor side effects and overall well-being. Even after active participation ends, many trials include long-term follow-up visits or remote check-ins to track ongoing effects and ensure safety over time.
3.2 How to Prepare Your Family
- Get organized. Keep your child’s medical records up to date and easy to access. This includes your genetic report, diagnosis letter, seizure logs, medication lists, and recent medical summaries. Having these ready speeds up the screening process when a trial opportunity arises.
- Plan for logistics. Talk with your family, school, and employers early about the time and travel that may be required. Some trials involve frequent clinic visits, while others require overnight stays or sedation for certain procedures. Having a plan for childcare, transportation, and work flexibility can ease the transition into a study schedule.
- Stay informed. Sign up for updates through the CURE SYNGAP1 Connect registry, look for opportunities on the CURE SYNGAP1 website, listen to podcasts, attend webinars, and participate in family research meetings. These channels provide early announcements about upcoming trials and opportunities for involvement.
- Ask questions. Before agreeing to participate, ask the study team to explain:
- What exactly will my child experience at each visit?
- How will the study protect my child’s safety and privacy?
- Are there travel stipends or family support available?
- What happens if my child has a side effect or wants to stop participating?
- Will we have access to results or follow-up care after the study ends?
- Prepare emotionally. Trials can be exciting but also emotionally demanding. There may be long waits between visits, uncertainty about results, and the possibility of being assigned to a placebo group. It’s okay to ask for emotional support — from your care team, a social worker, or other SYNGAP1 parents who have participated in research. Remember: choosing whether or not to participate is a personal decision, and both choices contribute to the community’s progress.
3.3 Expectations: What Families Should Know Before Enrolling
Participating in an early-phase clinical trial — especially a Phase 1 or Phase 1/2 study — is a meaningful commitment. These studies are designed primarily to evaluate safety, dosing, and how the treatment behaves in the body. Because of this, they can involve more procedures, closer monitoring, and a heavier visit schedule than later-phase trials. It’s important for families to go into the process with a realistic understanding of what participation may look like:
- Early-phase trials test safety first. Not every new therapy will show benefit in its earliest stages. These trials are designed to gather the foundational information researchers need to determine whether a treatment is safe enough — and promising enough — to move forward. Even when there is no obvious short-term improvement, every participant’s data directly shapes the future of SYNGAP1 therapies.
- Trial participation requires flexibility and prioritization. Families may need to rearrange parts of daily life during the study period. This can include:
- Missing school or therapy appointments
- Traveling for visits (sometimes with short notice)
- Managing sedation or recovery after procedures
- Coordinating care for siblings or work schedules
These demands can be temporary but intense. Planning ahead — and understanding the commitment upfront — can make participation smoother for everyone involved.
- Staying in the study is important — unless safety is at stake. Because early-phase trials rely on small numbers of participants, each family’s continued involvement is essential for generating meaningful data. Withdrawing early makes it harder for researchers to interpret results and slows progress for future SYNGAP1 families.
- That said, your child’s health and safety always come first. Leaving a trial is appropriate if recommended by the study team or if participation is no longer safe or medically appropriate. Convenience alone, however, should not be the reason to withdraw.
- Approval opens the door for more families. When a therapy eventually receives regulatory approval (from agencies like the FDA or EMA), access typically broadens. Early participants help establish the evidence that brings treatments to the wider community. Every visit completed, every assessment logged, and every sample collected contributes to that goal.
3.4 Family Takeaway
Clinical trials represent the bridge between scientific discovery and real-world therapy. For families, participation can be deeply meaningful — not just as a chance to help their own child, but to advance knowledge for every SYNGAP1 family worldwide. The process can be demanding, but being informed, organized, and emotionally prepared makes a big difference.Every question asked, every visit completed, and every data point shared brings us one step closer to safe, effective treatments for SYNGAP1-Related Disorders.